Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
α-synuclein fibril
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "α-synuclein fibril" in MCE Product Catalog:
2
Target:
Research Areas:
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
Cat. No.: HY-160116
CAS No.: 1565797-17-2
Research Areas:
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
Cat. No.: HY-N0698
CAS No.: 55750-84-0
Category:
Neurological Disease Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Disease Research Fields Inflammation/Immunology
Target:
Synonyms: UCB0599; (R)-NPT200-11
Target:
Research Areas:
Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
Target:
Target:
Research Areas:
CNS-11 is a brain-penetrant tau fibril-degrading compound. CNS-11 reduces α-synuclein. CNS-11 can be used in Alzheimer's and Parkinson's disease research .
Target:
Cat. No.: HY-N0413
CAS No.: 98243-57-3
Cat. No.: HY-P5082
CAS No.: 2243207-00-1
Target:
Research Areas:
Cat. No.: HY-401209
CAS No.: 613226-91-8
Target:
Research Areas:
Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC50 of 2.9 µM and a Kd value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease .
Cat. No.: HY-178920
CAS No.: 676458-63-2
Target:
Research Areas:
α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC50 value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .
Cat. No.: HY-D2002
CAS No.: 1219127-42-0
Cat. No.: HY-149509
CAS No.: 1510825-03-2
Target:
Research Areas:
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
Cat. No.: HY-157225
CAS No.: 3040318-36-0
Target:
Research Areas:
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .
Cat. No.: HY-186234
CAS No.: 2648041-95-4
Target:
Research Areas:
α-Synuclein aggregate binder 3 is a probe for α-synuclein aggregates. The Ki value of α-Synuclein aggregate binder 3 for binding to sonicated α-synuclein fibrils is 0.8 nM. α-Synuclein aggregate binder 3 can be used for α-synuclein imaging, as well as for detecting disorders associated with α-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy .
Cat. No.: HY-168647
Target:
Research Areas:
KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils .
Cat. No.: HY-N0698R
CAS No.: 55750-84-0
Cat. No.: HY-184511
CAS No.: 2648041-73-8
Target:
Research Areas:
MODAG-005 is a blood-brain barrier-permeable PET probe precursor for α-synuclein (α‑Syn) aggregates, with a Ki value of 0.4 nM and a Kd value of 0.2 nM. MODAG-005 specifically binds to high-affinity sites within the tubular cavity of α-synuclein fibrils, and exhibits selectivity over tau protein fibrils and β-amyloid (A1-42) fibrils. MODAG-005 is applicable to the research of multiple system atrophy and Parkinson's disease .
Cat. No.: HY-N0413R
CAS No.: 98243-57-3
Cat. No.: HY-178276
CAS No.: 1394328-54-1
Target:
Research Areas:
α-Synuclein-IN-18 (Compound Mol D) is an inhibitor of the autocatalytic proliferation of α-Synuclein aggregate. α-Synuclein-IN-18 can specifically bind to the conserved binding pocket on the surface of α-synuclein fibrils. α-Synuclein-IN-18 can delay the aggregation process of α-synuclein, extend the aggregation T1/2 by three times. α-Synuclein-IN-18 can reduce the generation flux of α-synuclein toxic oligomers, thereby alleviating the neurotoxicity. α-Synuclein-IN-18 can be used for research of Parkinson’sdisease .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
